Todd Krueger
Directeur Général chez AOBiome LLC
Profil
Todd Krueger is currently the President, Chief Executive Officer & Director at AOBiome LLC.
He is also the President & Chief Executive Officer at AOBiome Therapeutics, Inc. Additionally, he serves as the Director at Isolation Bio, Inc. Mr. Krueger completed his undergraduate degree at Northwestern University and holds an MBA from Kellogg School of Management.
Postes actifs de Todd Krueger
| Sociétés | Poste | Début |
|---|---|---|
AOBiome LLC
 AOBiome LLC Pharmaceuticals: MajorHealth Technology AOBiome LLC develops and commercializes skin care products. The firm operates an application of AOB that has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need. It has six ongoing clinical programs in acne vulgaris, or acne, allergic rhinitis, migraine, atopic dermatitis, or eczema, rosacea and hypertension, and multiple ongoing preclinical programs, including pulmonary and gastrointestinal disorders. The company was founded by Jamie Heywood, Lenny Barshack, Spiros Jamas, and David Whitlock in 2013 and is headquartered in Cambridge, MA. | Directeur Général | 01/04/2015 |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Directeur Général | - |
Isolation Bio, Inc.
 Isolation Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Isolation Bio, Inc. provides microbiology tools for microbiology research, and product development. It focuses on human health, agriculture, energy production, and synthetic biology. The company was founded by Peter Christey, Michael Seely, Paul Blainey, and Roman Stocker in 2014 and is headquartered in San Carlos, CA. | Directeur/Membre du Conseil | 04/11/2014 |
Formation de Todd Krueger
| Northwestern University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Isolation Bio, Inc.
Isolation Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Isolation Bio, Inc. provides microbiology tools for microbiology research, and product development. It focuses on human health, agriculture, energy production, and synthetic biology. The company was founded by Peter Christey, Michael Seely, Paul Blainey, and Roman Stocker in 2014 and is headquartered in San Carlos, CA. | Commercial Services |
AOBiome LLC
AOBiome LLC Pharmaceuticals: MajorHealth Technology AOBiome LLC develops and commercializes skin care products. The firm operates an application of AOB that has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need. It has six ongoing clinical programs in acne vulgaris, or acne, allergic rhinitis, migraine, atopic dermatitis, or eczema, rosacea and hypertension, and multiple ongoing preclinical programs, including pulmonary and gastrointestinal disorders. The company was founded by Jamie Heywood, Lenny Barshack, Spiros Jamas, and David Whitlock in 2013 and is headquartered in Cambridge, MA. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
